BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2015;Epub ahead of print. [PMID: 25918016 DOI: 10.1038/tpj.2015.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Salum GM, Dawood RM, Abd El-Meguid M, Ibrahim NE, Abdel Aziz AO, El Awady MK. Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients. Genes Dis 2020;7:392-400. [PMID: 32884993 DOI: 10.1016/j.gendis.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Duffy D, Mottez E, Ainsworth S, Buivan TP, Baudin A, Vray M, Reed B, Fontanet A, Rohel A, Petrov-Sanchez V, Abel L, Theodorou I, Miele G, Pol S, Albert ML. An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms. PLoS One 2017;12:e0183084. [PMID: 28877177 DOI: 10.1371/journal.pone.0183084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, Siadat SD. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 2017;18:144-51. [DOI: 10.1038/gene.2017.12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Pecoraro V, Cariani E, Villa E, Trenti T. Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. Eur J Clin Invest 2016;46:737-48. [PMID: 27376688 DOI: 10.1111/eci.12656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
6 Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Sharafi H. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e37011. [PMID: 27630727 DOI: 10.5812/hepatmon.37011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]